Federica Tomao

Dr. Federica Tomao

a. Department of Gynecologic Oncology, European Institute of Oncology (IEO) IRCCS, Milan,
+2

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in OncoTargets and Therapy
Verified
Journal Article
Open access
Claudia MarchettiClaudia Marchetti
Claudia Marchetti
MGMargherita Giorgini
Margherita Giorgini
CMCaterina De Medici
Caterina De Medici
IPInnocenza Palaia
Innocenza Palaia
RIRoberta Iadarola
Roberta Iadarola
FTFederica Tomao
Federica Tomao
Ovarian cancer is the most common cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease; although chemotherapeutic advances have improved progression-free survival, conventional treatments offer limited results in terms of long-term responses and survival. Research has recently focused on targeted therapies, which represent a new, promising therapeutic approach, aimed to maximize tumor kill and minimize toxicity. Besides antiangiogenetic agents and poly (ADP-ribose) polymerase inhibitors, the folate, with its membrane-bound receptor, is currently one of the most investigated alternatives. In particular, folate receptor (FR) has been shown to be frequently overexpressed on the surface of almost all epithelial ovarian cancers, making this receptor an excellent tumor-associated antigen. There are two basic strategies to targeting FRs with therapeutic intent: the first is based on anti-FR antibody (ie, farletuzumab) and the second is based on folate–chemotherapy conjugates (ie, vintafolide/etarfolatide). Both strategies have been investigated in Phase III clinical trials. The aim of this review is to analyze the research regarding the activity of these promising anti-FR agents in patients affected by ovarian cancer, including anti-FR antibodies and folate–chemotherapy conjugates.

1 January 2015 in OncoTargets and Therapy
Verified
Journal Article
Open access
FTFederica Tomao
Federica Tomao
APAnselmo Papa
Anselmo Papa
EZEleonora Zaccarelli
Eleonora Zaccarelli
LRLuigi Rossi
Luigi Rossi
DCDavide Caruso
Davide Caruso
STSilverio Tomao
Silverio Tomao
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors. It has became apparent that this diversity may be justified by distinct patterns of genetic, epigenetic, and transcriptomic aberrations. The identification of gene-expression microarray-based characteristics has led to the identification of at least five breast cancer subgroups: luminal A, luminal B, normal breast-like, human epidermal growth factor receptor 2, and basal-like. Triple-negative breast cancer is a complex disease diagnosed by immunohistochemistry, and it is characterized by malignant cells not expressing estrogen receptors or progesterone receptors at all, and human epidermal growth factor receptor 2. Along with this knowledge, recent data show that triple-negative breast cancer has specific molecular features that could be possible targets for new biological targeted drugs. The aim of this article is to explore the use of new drugs in this particular setting, which is still associated with poor prognosis and high risk of distant recurrence and death.

8 May 2018 in European Radiology
Verified
Journal Article
Closed access
PDF file
SRStefania Rizzo
Stefania Rizzo
FBFrancesca Botta
Francesca Botta
SRSara Raimondi
Sara Raimondi
DODaniela Anna Origgi
Daniela Anna Origgi
VBValentina Buscarino
Valentina Buscarino
MBMassimo Bellomi
Massimo Bellomi

29 October 2019 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
EKE. Krasniqi
E. Krasniqi
GBG. Barchiesi
G. Barchiesi
LPL. Pizzuti
L. Pizzuti
MMMarco Mazzotta
Marco Mazzotta
Venuti AldoVenuti Aldo
Venuti Aldo
PVPatrizia Vici
Patrizia Vici
Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatment, including the human epidermal growth factor 2 positive (HER2+) subtype. The immune system holds the ability to spontaneously implement a defensive response against HER2+ BC cells through complex mechanisms which can be exploited to modulate this response for obtaining a clinical benefit. Initial immune system modulating strategies consisted mostly in vaccine therapies, which are still being investigated and improved. However, the entrance of trastuzumab into the scenery of HER2+ BC treatment was the real game changing event, which embodied a dominant immune-mediated mechanism. More recently, the advent of the immune checkpoint inhibitors has caused a new paradigm shift for immuno-oncology, with promising initial results also for HER2+ BC. Breast cancer has been traditionally considered poorly immunogenic, being characterized by relatively low tumor mutation burden (TMB). Nevertheless, recent evidence has revealed high tumor infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in a considerable proportion of HER2+ BC patients. This may translate into a higher potential to elicit anti-cancer response and, therefore, wider possibilities for the use and implementation of immunotherapy in this subset of BC patients. We are herein presenting and critically discussing the most representative evidence concerning immunotherapy in HER2+ BC cancer, both singularly and in combination with therapeutic agents acting throughout HER2-block, immune checkpoint inhibition and anti-cancer vaccines. The reader will be also provided with hints concerning potential future projection of the most promising immutherapeutic agents and approaches for the disease of interest.

11 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LRLuigi Rossi
Luigi Rossi
MVMonica Verrico
Monica Verrico
EZEleonora Zaccarelli
Eleonora Zaccarelli
APAnselmo Papa
Anselmo Papa
MCMaria Colonna
Maria Colonna
FTFederica Tomao
Federica Tomao
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line treatment of advanced OC and for platinum-sensitive and platinum-resistant recurrent OC. These trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, BV effectively improved the quality of life with regard to abdominal symptoms in recurrent OC patients. Bevacizumab is associated with adverse events such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed. This review describes the latest evidence for BV treatment of OC and selection of patients for personalized treatment.

1 January 2014 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
Maria Grazia PorporaMaria Grazia Porpora
Maria Grazia Porpora
FTFederica Tomao
Federica Tomao
Lucia ManganaroLucia Manganaro
Lucia Manganaro
DYDeliar Yazdanian
Deliar Yazdanian
EFEliana Fuggetta
Eliana Fuggetta
Giuseppe BenagianoGiuseppe Benagiano
Giuseppe Benagiano
Aim of this prospective, case–control study was to evaluate uterine arteries’ blood flow before and after laparoscopic surgery in patients with ovarian endometriosis and its possible correlation with infertility.